We have developed a novel blood lysis-centrifugation approach for highly sensitive Mycobacterium tuberculosis detection in large volumes of blood with the Xpert MTB/RIF assay. One through 20 ml of blood was spiked with 0.25 to 10 CFU/ml of the M. tuberculosis surrogate M. bovis BCG. Multiple replicates of each sample were processed by a new lysis-centrifugation method and tested with the Xpert MTB/RIF assay. The assay was very sensitive with increased blood volumes. In the 20-ml samples, BCG was detected in blood spiked with 10, 5, 1, and 0.25 CFU/ml 100, 100, 83, and 57% of the time, respectively, compared to 100, 66, 18, and 18%, of the time, respectively, in 1-ml blood samples. Assay sensitivity was influenced by the type of anticoagulant used, with acid-citrate-dextrose solution B (ACD-B) providing the best results. A limit of detection of 10 CFU/ml was established with BCG spiked into ACD-B-treated blood, and 92, 36, and 33% of the samples with 5, 1, and 0.5 CFU/ml, respectively, were assay positive. The lysis buffer was stable both at room temperature and at 4°C for 2 months. The assay was tested with blood stored for 8 days without a change in sensitivity as measured by cycle threshold. This new assay format extends the capability of the Xpert MTB/RIF test, enabling up to 20 ml of blood to be tested rapidly for the presence of M. tuberculosis. This approach may be a useful method to detect extrapulmonary tuberculosis and the risk of death in immunocompromised patients.
T uberculosis (TB) is one of the leading causes of death from an infectious disease worldwide (1) . Diagnostic delays contribute significantly to death. In the case of pulmonary TB (PTB), a diagnosis can often be made by testing expectorated sputum samples. However, some patients are not able to expectorate sputum, especially if they are very sick or young. Extrapulmonary TB (EPTB) is common (2, 3) , especially in patients with human immunodeficiency virus (HIV) infection. The death rate among subjects with dual HIV and Mycobacterium tuberculosis infections can be very high (4, 5) . EPTB is usually diagnosed by performing microscopic, culture-based, or nucleic acid amplification tests (NATs) of aspirated fluid or tissue biopsy material, depending on the site that is infected (6, 7) . Microscopy has a low sensitivity for the diagnosis of EPTB, and reliance on culture-based detection methods can lead to substantial delays in diagnosis (8, 9) . Rapid TB NATs have not been optimized for nonpulmonary samples and have had variable performance in detecting TB in tissue or fluid samples (9) (10) (11) (12) . Thus, there is a real need for improved methods to test extrapulmonary samples.
Blood is an attractive option for the detection of TB, especially in HIV-infected patients. Blood is easier and more reliable to sample than sputum, especially in patients who are confused or obtunded or who do not have a productive cough. M. tuberculosis can be cultured from 2 to 64% of the blood samples collected, depending on the study population (13) . In sub-Saharan Africa, M. tuberculosis is a common cause of bacteremia, accounting for 54% of all bloodstream infections (BSI), especially among HIVpositive patients (14) . Furthermore, disseminated M. tuberculosis infection resulting in a BSI may be an important predictor of death (4, 5) .
M. tuberculosis is rarely detected by blood tests despite the potential advantages of this approach. TB blood culture usually takes several weeks to become positive and requires appropriately equipped facilities (15, 16) . NATs such as the PCR have been investigated, but sensitivity with blood has been poor (20 to 55%) (4, (17) (18) (19) (20) (21) . This could be due in part to the presence of PCR inhibitors (22, 23) . The poor sensitivity of blood-based NATs could also be due to the small volume of blood (500 l to Ͻ5 ml) that is usually collected for these tests. These small volumes could make it difficult or impossible to detect M. tuberculosis circulating in blood if the bacteria are present at very low densities. However, 5 to 10 ml of blood is typically used for blood cultures (24, 25) . NATs for TB might have sensitivities equal to or greater than that of blood culture if similar volumes of blood could be tested by improved sample-processing methods.
The Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA) has greatly simplified TB detection in sputum samples (26) (27) (28) . This completely automated real-time PCR assay simultaneously detects the presence of M. tuberculosis and rifampin resistance (29) . The assay is approximately 98.3% sensitive and 99% specific for detecting M. tuberculosis in sputum samples (26, 29) . Sensitivity with extrapulmonary samples has varied from 25 to 100%, depending on the body site and study (17) (18) (19) (20) 30) . The ability of the Xpert MTB/RIF assay to detect M. tuberculosis in blood has not been investigated, and the current sample-processing protocol used in the Xpert MTB/RIF assay has not been previously optimized for blood. For example, the current Xpert MTB/RIF protocol uses 1 ml of sputum, while a protocol for blood should arguably start with larger sample volumes.
Here, we present a novel lysis and centrifugation approach that permits relatively large volumes of blood to be tested with the Xpert MTB/RIF assay. Analytic results suggest that our new ap-SR and incubated for 15 min. The blood-SR mixture was then loaded into the sample loading chamber of an Xpert MTB/RIF assay cartridge. Subsequent sample processing and PCR were then performed in accordance with the manufacturer's recommendations for sputum samples (Cepheid).
Effect of blood volume on detection of very low levels of M. tuberculosis in blood. To determine the effect of blood sample volume on sensitivity for M. tuberculosis, BCG cells were spiked at concentrations of 0.25, 1, 5, and 10 CFU/ml into various volumes of reconstituted banked blood. Blood samples were processed as described above. All of the samples were run in replicates of seven.
LOD of mycobacteria in ACD-B-treated blood. ACD-B proved to be the best-performing anticoagulant in our tests. Therefore, the LOD was established with the blood from healthy volunteers collected in ACD-B anticoagulant tubes (BD). M. bovis BCG was spiked at concentrations of 0.5, 1, 5, 10, and 50 CFU/ml into 10 ml of ACD-B-treated blood. All of the samples were processed in accordance with the lysis centrifugation protocol. Seven and 8 replicates were run for each cell concentration in two separate experiments or runs, for a total of 15 replicates.
Stability of solution 2.2.1. RBC lysis solution 2.2.1 was prepared and stored at both RT and under refrigerated conditions (4 to 8°C) for up to 3 months. The aliquoted tubes were removed at days 1, 7, and 15, followed by 1, 2, 3 months, and tested as follows. For each time point, reconstituted banked blood was spiked with 10 CFU/ml of BCG per 10 ml of blood. RBC lysis solution 2.2.1 was added at 15% vol/vol (1.5 ml per 10 ml) and the blood was processed as described above. Stability was assessed by the average cycle threshold (C T ) of the first rpoB probe measured in the Xpert MTB/RIF assay, with increasing C T s indicative of degraded performance.
Storage of BCG-infected blood at refrigerated temperature. Tests were performed to understand how long ACD-B-anticoagulated blood could be stored in the refrigerator before processing. BCG was spiked into 10 ml of ACD-B-treated blood at 10 CFU/ml and stored in a refrigerator (2 to 8°C) for up to 8 days. The sample was removed and processed with solution 2.2.1 in accordance with the protocol described above. The effect of storage time was evaluated by observing any change in the C T or the endpoint fluorescence values in the first rpoB probe measured in the Xpert MTB/RIF assay.
Statistical analysis. Analysis (average, standard deviation, and t test) was performed with Microsoft Excel 2000 for Windows. One-way analysis of variance (ANOVA) for independent or correlated samples was carried out to evaluate the P values with the online ANOVA calculator ay http: //faculty.vassar.edu/lowry/anova1u.html. Curve fitting for the LOD curve was done by sigmoid linear regression analysis with SigmaPlot V8.0.
RESULTS

Large volumes of blood allow M. tuberculosis detection and outperform small volumes.
We developed a protocol that enabled us to lyse up to 20 ml of blood, concentrate any M. tuberculosis present in the sample by centrifugation, and resuspend the resulting pellet in Xpert SR. The resulting sample was then suitable for testing by the standard sputum protocol. We tested this approach by spiking BCG at 0.25 to 10 CFU/ml into different volumes of (blood-banked) blood ranging from 1 to 20 ml. The 1-ml blood samples were processed without lysis and centrifugation by being mixed with equal volumes of SR, and then the 2-ml mixtures were loaded into Xpert MTB/RIF assay cartridges. The larger blood volume samples were processed by our novel lysis-centrifugation protocol. As shown in Fig. 2 , increasing the volume of blood that was tested resulted in a substantially increased rate of positive results, especially for tests performed with 0.25-, 1-, and 5-CFU/ml samples. Blood volumes of 20 ml that were spiked with as few as 0.25 and 1 CFU/ml could be detected consistently 57 and Ͼ80% of the time, respectively. However, in a smaller blood volume of 1 ml, the same cell concentrations were detected Ͻ20% of Snap vortex and load the whole 2 ml into the sample chamber of the Xpert MTB/RIF assay cartridges. Run the normal Xpert MTB/RIF protocol. the time. Thus, 1-ml blood samples needed to be spiked with 5 to 10 times more M. tuberculosis CFU than 20-ml blood samples to achieve similar rates of test positivity.
We considered the possibility that our lysis and centrifugation method might concentrate PCR inhibitors at the same time that it concentrated M. tuberculosis bacilli. The Xpert MTB/RIF assay includes a sample-processing control assay for Bacillus globigii that can also be used to indicate the presence of PCR inhibitors (34) . Inhibition is detected by an increase in the B. globigii C T . We did not observe any increase in the B. globigii C T with increasing blood volumes, suggesting that our procedure did not concentrate significant amounts of inhibitors of the Xpert MTB/RIF assay.
Role of anticoagulants in M. tuberculosis detection in blood. Our processing protocol requires anticoagulated blood samples. However, certain anticoagulants such as heparin or EDTA can inhibit PCR assays. We tested the impact of various anticoagulants on assay sensitivity after large-volume lysis and centrifugation. We selected anticoagulants for testing on the basis of their use in commonly available commercial blood collection tubes. Blood was drawn from human volunteers into collection tubes containing ACD-A, ACD-B, or EDTA. BCG was spiked into 5-ml aliquots of each sample at 5-and 10-CFU/ml concentrations. The samples were then processed by our lysis and centrifugation protocol and tested with the Xpert MTB/RIF assay. As shown in Fig. 3 , the ACD-anticoagulated blood showed the best overall performance. M. tuberculosis was detected in 100% of the test aliquots containing 10 CFU/ml that were anticoagulated with either ACD-A or ACD-B and in 100% of the test aliquots containing 5 CFU/ml that were anticoagulated with ACD-B (ACD-A was not tested at 5 CFU/ml). This is in contrast to the EDTA-anticoagulated samples, which had substantially fewer positive test results. Comparing the rpoB values of the ACD-A-and ACD-B-anticoagulated samples containing 10 CFU/ml, we noted that ACD-A anticoagulation resulted in a delayed mean C T (29.7 Ϯ 0.5 versus 28.1 Ϯ 1, P ϭ 0.015). This suggested that ACD-B anticoagulation would provide the best assay sensitivity.
LOD with ACD-B-anticoagulated blood. We determined the LOD of our lysis and centrifugation protocol with blood anticoagulated with ACD-B, since this appeared to be the best candidate for eventual clinical studies. We found that our approach identified M. tuberculosis 100% of the time in aliquots containing 50 and 10 CFU/ml, defining the LOD as 10 CFU/ml. However, the assay continued to perform well even with lower inoculum concentrations, detecting M. tuberculosis in 91.6% of the blood samples spiked with 5 CFU/ml, 36% of those spiked with 1 CFU/ml, and 33% of those spiked with 0.5 CFU/ml (Fig. 4) . Overall, the performance of the ACD-B-anticoagulated blood samples was similar to what we observed with CPDA-anticoagulated banked blood (Fig.  2) , suggesting that banked blood can be used for future analytic studies.
Stability studies. Our assay might be useful in clinics or laboratories that do not have the capacity to easily make our lysis solution. Therefore, we performed stability studies to determine how long the lysis solution could be stored without affecting assay performance. The solution was stored at both RT (20 to 25°C) and 4°C for up to 3 months. Aliquots were removed periodically to process blood samples spiked with known numbers of BCG CFU/ml. The C T of the first rpoB probe was used to asses assay performance (Fig. 5A) . The storage temperature of the lysis buffer did not appear to affect the rpoB C T (95% confidence interval, P ϭ 0.8).
Laboratories might find it convenient to batch test blood samples, or blood might need to be transported to off-site locations. To study how long blood could be stored at 4°C prior to processing, we spiked 10 CFU/ml of BCG into 10-ml aliquots of ACD-Banticoagulated blood and then stored the samples at 4°C for up to (Fig. 5B) . All assays were positive at all time points, and no difference in assay C T s was noted even after the 8-day time point. This study suggests that M. tuberculosis is stable in human blood stored at 4°C for at least 8 days and that large-volume sample processing can be delayed for at least 1 week without affecting assay performance.
DISCUSSION
The major findings of this study were that a simple preprocessing step can be used to sensitively detect M. tuberculosis in large volumes of blood with the Xpert MTB/RIF assay. Important assay parameters affecting sensitivity of detection include the blood volumes and the anticoagulants used.
Our proposed lysis centrifugation protocol has several notable advantages over prior assays to detect M. tuberculosis in blood. First, our lysis buffer was more concentrated (used at a 0.15:1 ratio with blood) than most of the blood lysis buffers reported, which use much higher ratios, usually 1:1 to 10:1. The limited volume requirement of the lysis buffer made it possible to lyse large blood volumes in blood collection tubes or by transferring the collected blood sample into a simple test tube that was prefilled with lysis buffer. These procedures simplified the technical components of the assay. Second, we showed that our lysis buffer completely removes PCR inhibitors, in the context of the Xpert MTB/RIF assay. This property made it possible for us to test very large blood volumes in this study, up to 20 ml, without adding measurable inhibitors to the PCR mixture. The ability to test large blood volumes enabled us to achieve substantial gains in sensitivity. Finally, we show that our assay has acceptable reagent and sample stability.
Our goal was to develop the most sensitive blood PCR assay possible for M. tuberculosis. This was based on the assumption that M. tuberculosis bacteria are present in the blood of TB patients at very low concentrations, when they are present at all. We are not aware of any studies that have formally examined this question in the case of M. tuberculosis. However, for other microbial pathogens, bacterial loads of Ͻ1 CFU/ml have been reported among septic adult patients (35) . Furthermore, the volume of blood tested by blood culture is considered to be the single most important factor in the detection of bacteria in the blood of adult patients (36) (37) (38) . Each additional 1 ml of blood cultured increases microbial recovery by up to 3% (36, (39) (40) (41) . Thus, we expect that our large-volume approach will substantially improve M. tuberculosis detection.
It is unlikely that our method of using the Xpert MTB/RIF assay with blood will diagnose all forms of TB with equal sensitivity. Rebollo et al. (20) noted that the sensitivity of PCR and culture of blood for M. tuberculosis detection was greatest in patients with disseminated TB and those with HIV confection. These are patient groups that frequently do not have a productive cough. Thus, it is likely that our approach will be especially useful in a subset of TB cases that are particularly poorly served by current diagnostics.
Several anticoagulants that are used to collect blood from patients can be PCR inhibitory and will affect assay sensitivity if not properly removed from the sample (42, 43) . Heparin is a known PCR inhibitor (42, 44) . EDTA can chelate the Mg 2ϩ present in PCR buffer, thus affecting PCR assay performance (45) . Isolator tubes recommended for lysis and centrifugation of blood cultures contain high concentrations of saponin and sodium polyanetholesulfonate, which have been shown to be inhibitory to PCR-based blood assays (46) . In the present study, we examined blood collected in EDTA, CPDA (banked blood), and two different commercial ACD-anticoagulated tubes (ACD-A and ACD-B). In ACD, citric acid prevents coagulation by binding to calcium and dextrose acts as an RBC nutrient and preservative by maintaining RBC viability. It contains no known PCR inhibitors and thus was a good candidate for our studies. Of the two different ACD formulations available in commercial blood-drawing tubes, ACD-A is more concentrated (BD Vacutainer venous blood collection tube guide). It did not perform as well as ACD-B in our study, possibly because high concentrations of citrate in ACD-A might have mildly inhibited the PCR.
In summary, we have shown that it is possible to test large volumes of blood for the presence of M. tuberculosis with the existing Xpert MTB/RIF platform. Our approach can test samples as large as 20 ml of blood and has a detection limit of 5 to 10 CFU/ml. Bacterial titers as low as 0.25 to 1 CFU/ml can also be routinely detected, although there will be some false-negative assay results at the low end of this titer range. The sample-processing protocol we developed takes approximately 1 h. Combined with the Xpert MTB/RIF on-machine time, the time to result of this assay can be as low as 3 h from the initial blood drawing. This time frame compares very favorably to the several-week delay that is typical for M. tuberculosis blood cultures and may enable rapid diagnosis for a patient group that will particularly benefit from rapid diagnosis and initiation of treatment. The high sensitivity that we observed in our analytic study suggests that our approach may have clinical utility. However, it is necessary to perform clinical trials with relevant patient populations before clinical sensitivity and specificity can be established.
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